The Prognostic Value of Systemic Inflammation Index in Breast Cancer: A Retrospective Study in Western Romania

• Published in: Journal of clinical medicine 2025-02, Vol.14 (4), p.1081
• Main Authors: Ciurescu, Sebastian, Tomescu, Larisa, Șerban, Denis, Nicolae, Nicoleta, Nan, Georgiana, Buciu, Victor, Ilaș, Diana-Gabriela, Cîtu, Cosmin, Vernic, Corina, Sas, Ioan
• Format: Article
• Language: English
• ISSN: 2077-0383; 2077-0383
• DOI: 10.3390/jcm14041081

Background/Objectives: Breast cancer remains a leading cause of cancer-related morbidity worldwide, and refining prognostic tools is essential for individualized patient management. Recent evidence suggests that the systemic immune–inflammation index (SII), derived from routine blood tests, may offer valuable prognostic insights. This study aimed to evaluate whether SII can reliably predict clinical outcomes for patients undergoing curative resection. Methods: We retrospectively analyzed patients with histologically confirmed breast cancer who underwent surgical intervention at a single tertiary center. Preoperative complete blood counts were used to calculate SII. Using receiver operating characteristic (ROC) curve analysis, we identified an optimal SII cutoff. Using statistical tests, including t-tests and ANOVA, we examined differences in clinicopathological factors between low- and high-SII groups. Using univariate and multivariate analyses, we explored associations between SII and variables such as tumor stage and hormone receptor status. Results: Patients with elevated SII levels showed significant associations with more advanced tumor stage and systemic inflammatory profiles. The identified SII cutoff separated patients into distinct risk groups, and high SII values correlated with poorer prognostic features. Multivariate models indicated that SII provided additional predictive value beyond standard markers. Conclusions: Our findings suggest that SII may provide prognostic insights into breast cancer, particularly in stratifying patients based on inflammatory profiles. However, the current study does not support the use of SII as a clinical tool for tailoring treatment strategies. Further preclinical and randomized controlled trials are required to determine its predictive utility and to assess its potential integration into personalized management approaches.